Jaguar Health
JAGX · Nasdaq · United States
Share price · JAGX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when JAGX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 22 Sep 2026+1190.6%
- 17 Sep 2026-21.3%
Nothing announced by JAGX that day or the session before.
- 15 Sep 2026-29.6%
- 8 Sep 2026-30.6%
- Day beforeJaguar Health: Other material event
- 14 Aug 2026+17.0%
- Day beforeEarnings date (period ending 2026-06-30)
- 23 Jul 2026-22.6%
Nothing announced by JAGX that day or the session before.
- 16 Jul 2026-31.5%
Nothing announced by JAGX that day or the session before.
- 4 May 2026-51.4%
- 27 Apr 2026-27.8%
- 20 Jan 2026-40.2%
Nothing announced by JAGX that day or the session before.
Share of unusual movement by asset
For each asset, the share of JAGX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Crofelemer (Mytesi)events and moves
| 3 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 98% |
| Sessions with no dated event | — | 2% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Crofelemer(Mytesi) | Approved | Chloride channel (intestinal epithelium)Small molecule | Short Bowel SyndromeHIV-Associated Diarrhea |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
March 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $1.2M | $3.3M | $6.6M | —-$5.3M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $20M | $3.9M | $10M | —$8.8M operating cash flow | report ↗ |
| 2025-Q3 | $3.1M | $3.7M | $3.5M | $9.5M-$4.7M operating cash flow | report ↗ |
| 2025-Q2 | $3.0M | $3.3M | $2.2M | $10M-$6.2M operating cash flow | report ↗ |
| 2025-Q1 | $2.2M | $3.7M | $5.7M | $10M-$7.3M operating cash flow | report ↗ |
| 2024-Q3 | $3.1M | $4.0M | $13M | $9.8M-$6.3M operating cash flow | report ↗ |
| 2024-Q2 | $2.7M | $3.6M | $16M | $9.5M-$8.2M operating cash flow | report ↗ |
| 2024-Q1 | $2.4M | $4.3M | $12M | $9.2M-$7.0M operating cash flow | report ↗ |
| 2023-Q3 | $2.8M | $6.1M | $3.2M | $7.8M-$6.8M operating cash flow | report ↗ |
| 2023-Q2 | — | $4.3M | $8.6M | $12M-$9.1M operating cash flow | report ↗ |
| 2023-Q1 | — | $4.8M | $14M | $12M-$9.9M operating cash flow | report ↗ |
| 2022-Q3 | — | $5.9M | $11M | $13M-$8.5M operating cash flow | report ↗ |
| 2022-Q2 | — | $2.5M | $9.0M | $9.4M-$10M operating cash flow | report ↗ |
| 2022-Q1 | — | $5.0M | $17M | $18M-$7.7M operating cash flow | report ↗ |
| 2021-Q3 | — | $3.3M | $12M | $12M-$9.4M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $12M | $25M | $7.8M | $13M-$24M operating cash flow | report ↗ |
Jaguar Health reported FY 2025 revenue of $11.51M, down 1.5% YoY, with R&D spend of $24.97M, up 51.0% YoY. Cash and equivalents were $7.83M, and the company recorded a net loss of $53.57M, with a quarterly net burn of $53.58M.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2025-12-11 | MICEK JOHN · director | Award / grant | 7,377 | — | — | Form 4 |
| 2025-12-11 | MICEK JOHN · director | Award / grant (derivative) | 7,377 | — | — | Form 4 |
| 2025-12-11 | Wolin Jonathan S. · See Remarks | Award / grant | 11,740 | — | — | Form 4 |
| 2025-12-11 | CONTE LISA A · director, See Remarks | Award / grant | 28,592 | — | — | Form 4 |
| 2025-12-11 | King Steven R. · See Remarks | Award / grant | 11,740 | — | — | Form 4 |
| 2025-12-11 | Wolin Jonathan S. · See Remarks | Award / grant (derivative) | 11,740 | — | — | Form 4 |
| 2025-12-11 | CONTE LISA A · director, See Remarks | Award / grant (derivative) | 28,592 | — | — | Form 4 |
| 2025-12-11 | King Steven R. · See Remarks | Award / grant (derivative) | 11,740 | — | — | Form 4 |